Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
LQDA Stock Forecast 2026-2027
$79.94
Current Price
$6.69B
Market Cap
Buy 7
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to LQDA Price Targets
+36.4%
To High Target of $109.00
-11.8%
To Median Target of $70.50
-24.9%
To Low Target of $60.00
LQDA Price Momentum
+2.6%
1 Week Change
+12.5%
1 Month Change
+449.8%
1 Year Change
+131.8%
Year-to-Date Change
-3.6%
From 52W High of $82.96
+469.4%
From 52W Low of $14.04
📊 TOP ANALYST CALLS
Did LQDA Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if iShares Bond ETF is one of their latest high-conviction picks.
Latest LQDA Stock Price Targets & Analyst Predictions
Based on our analysis of 13 Wall Street analysts, LQDA has a bullish consensus with a median price target of $70.50 (ranging from $60.00 to $109.00). The overall analyst rating is Strong Buy (9.3/10). Currently trading at $79.94, the median forecast implies a -11.8% downside. This outlook is supported by 7 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Julian Harrison at BTIG, projecting a 36.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
LQDA Analyst Ratings
7
Buy
1
Hold
0
Sell
LQDA Price Target Range
Low
$60.00
Average
$70.50
High
$109.00
Current: $79.94
Latest LQDA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for LQDA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 29, 2026 | B of A Securities | Jason Gerberry | Neutral | Downgrade | $79.00 |
| Jun 22, 2026 | BTIG | Julian Harrison | Buy | Maintains | $109.00 |
| Jun 5, 2026 | HC Wainwright & Co. | Andrew S. Fein | Buy | Maintains | $75.00 |
| May 12, 2026 | HC Wainwright & Co. | Andrew S. Fein | Buy | Maintains | $67.00 |
| May 12, 2026 | Wells Fargo | Benjamin Burnett | Overweight | Maintains | $62.00 |
| May 11, 2026 | Needham | Serge Belanger | Buy | Maintains | $70.00 |
| May 11, 2026 | BTIG | Julian Harrison | Buy | Maintains | $59.00 |
| Mar 23, 2026 | Wells Fargo | Benjamin Burnett | Overweight | Maintains | $51.00 |
| Mar 12, 2026 | Oppenheimer | Andreas Argyrides | Underperform | Maintains | $19.00 |
| Mar 6, 2026 | Wells Fargo | Benjamin Burnett | Overweight | Maintains | $44.00 |
| Mar 6, 2026 | HC Wainwright & Co. | Andrew S. Fein | Buy | Maintains | $55.00 |
| Mar 5, 2026 | Needham | Serge Belanger | Buy | Maintains | $54.00 |
| Mar 5, 2026 | BTIG | Julian Harrison | Buy | Maintains | $50.00 |
| Feb 25, 2026 | Needham | Serge Belanger | Buy | Reiterates | $52.00 |
| Jan 13, 2026 | Jefferies | Amy Li | Buy | Maintains | $55.00 |
| Jan 13, 2026 | BTIG | Julian Harrison | Buy | Reiterates | $49.00 |
| Dec 26, 2025 | BTIG | Julian Harrison | Buy | Reiterates | $49.00 |
| Nov 4, 2025 | HC Wainwright & Co. | Andrew S. Fein | Buy | Maintains | $50.00 |
| Nov 4, 2025 | Needham | Serge Belanger | Buy | Maintains | $52.00 |
| Nov 4, 2025 | BTIG | Julian Harrison | Buy | Reiterates | $49.00 |
Liquidia Corporation (LQDA) Competitors
The following stocks are similar to iShares Bond ETF based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
LQDA
iShares Corp Bond ETF
mkt cap
6.93B
Liquidia Corporation (LQDA) Financial Data
Liquidia Corporation has a market capitalization of $6.69B with a P/E ratio of 457.4x. The company generates $288.06M in trailing twelve-month revenue with a 7.7% profit margin.
Revenue growth is +4,158.5% quarter-over-quarter, while maintaining an operating margin of +46.3% and return on equity of +28.2%.
Valuation Metrics
Market Cap
$6.69B
Enterprise Value
$6.76B
P/E Ratio
457.4x
PEG Ratio
-2.0x
Price/Sales
24.0x
Growth & Margins
Revenue Growth (YoY)
+4,158.5%
Gross Margin
+91.1%
Operating Margin
+46.3%
Net Margin
+7.7%
EPS Growth
+4,158.5%
Financial Health
Cash/Price Ratio
+3.1%
Current Ratio
2.2x
Debt/Equity
170.2x
ROE
+28.2%
ROA
+9.1%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Liquidia Corporation (LQDA) Business Model
About Liquidia Corporation
What They Do
Biopharmaceutical company focused on pulmonary therapies.
Business Model
The company develops and commercializes treatments for rare cardiopulmonary diseases, generating revenue primarily through the sale of its key product, Yutrepia, an inhaled dry powder for pulmonary hypertension. Additionally, Liquidia engages in licensing collaborations for its treprostinil-based therapies and explores various formulations to meet diverse patient needs.
Additional Information
Founded in 2004 and headquartered in Morrisville, North Carolina, Liquidia targets the U.S. market, working with pulmonologists and specialty clinics to address unmet medical needs in chronic respiratory care. Its focus on drug-delivery innovation positions it uniquely within the biotech sector.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
170
CEO
Dr. Roger A. Jeffs Ph.D.
Country
United States
IPO Year
2018
Website
www.liquidia.comLiquidia Corporation (LQDA) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
HRMY Posts Preliminary Q2 Revenues, Announces CFO Transition
Harmony Biosciences posts preliminary Q2 2026 Wakix revenues of about $261M, up 30% year over year, while reaffirming full-year guidance despite a CFO transition.
Jul 17, 2026
By Zacks Equity Research
Analyst Blog
Eli Lilly to Boost Neuroscience Pipeline With AtaiBeckley Buyout
LLY agrees to acquire AtaiBeckley for $2.8B upfront to expand its neuroscience pipeline with psychedelic therapies for mental health disorders.
Jul 17, 2026
By Zacks Equity Research
Analyst Blog
GSK Discontinues Development of Camlipixant for Refractory Chronic Cough
GSK drops camlipixant's refractory chronic cough program after mixed phase III results, but the drug remains in a phase IIb study for irritable bowel syndrome.
Jul 17, 2026
By Zacks Equity Research
Analyst Blog
Latest News
Quick Summary
LQDA's Yutrepia had a successful commercial launch; future growth will depend on its ability to differentiate in the competitive PAH market.
Why It Matters
LQDA's strong debut indicates initial market interest, but its future growth relies on differentiation in a competitive PAH market, impacting revenue potential and stock performance.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
LQDA, FLXS, ELMD, and AGX exhibit low beta, positive price momentum, and strong fundamentals, offering potential stability for investors amid market volatility.
Why It Matters
LQDA, FLXS, ELMD, and AGX offer stability with low beta, while their positive momentum and strong fundamentals suggest potential resilience during market fluctuations.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Liquidia's stock has risen 129.7% in 2026, fueled by increasing sales from Yutrepia, leading to improved profitability and higher earnings estimates.
Why It Matters
Liquidia's 129.7% surge indicates strong market confidence, driven by Yutrepia's sales growth, suggesting potential for continued profitability and upward earnings revisions.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
LQDA's Yutrepia generated $130 million in Q1 sales, with increasing prescriptions and profitability as the company expands its presence in pulmonary arterial hypertension (PAH).
Why It Matters
LQDA's strong Q1 sales and increasing profitability from the Yutrepia launch indicate robust market demand, potentially boosting stock value and investor confidence in the company’s growth.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Liquidia Corporation (LQDA) is being evaluated as a potential top stock pick for momentum investors. Further analysis is needed to determine its suitability.
Why It Matters
Liquidia Corporation's potential as a momentum stock could signal growth opportunities, affecting share price volatility and attracting speculative investments.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Top Wall Street analysts have updated their outlook on several major companies. For a full list of rating changes, including upgrades and downgrades, visit the analyst ratings page.
Why It Matters
Changes in analyst ratings can significantly influence stock prices, impacting investor sentiment and market trends. Upgrades may signal potential growth, while downgrades can indicate risks.
Source: Benzinga
Market Sentiment:
Negative
Frequently Asked Questions About LQDA Stock
What is Liquidia Corporation's (LQDA) stock forecast for 2027?
Based on our analysis of 13 Wall Street analysts, Liquidia Corporation (LQDA) has a median price target of $70.50. The highest price target is $109.00 and the lowest is $60.00.
Is LQDA stock a good investment in 2027?
According to current analyst ratings, LQDA has 7 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $79.94. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for LQDA stock?
Wall Street analysts predict LQDA stock could reach $70.50 in the next 12 months. This represents a -11.8% decrease from the current price of $79.94. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Liquidia Corporation's business model?
The company develops and commercializes treatments for rare cardiopulmonary diseases, generating revenue primarily through the sale of its key product, Yutrepia, an inhaled dry powder for pulmonary hypertension. Additionally, Liquidia engages in licensing collaborations for its treprostinil-based therapies and explores various formulations to meet diverse patient needs.
What is the highest forecasted price for LQDA Liquidia Corporation?
The highest price target for LQDA is $109.00 from Julian Harrison at BTIG, which represents a 36.4% increase from the current price of $79.94.
What is the lowest forecasted price for LQDA Liquidia Corporation?
The lowest price target for LQDA is $60.00 from at , which represents a -24.9% decrease from the current price of $79.94.
What is the overall LQDA consensus from analysts for Liquidia Corporation?
The overall analyst consensus for LQDA is bullish. Out of 13 Wall Street analysts, 7 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $70.50.
How accurate are LQDA stock price projections?
Stock price projections, including those for Liquidia Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 18, 2026 2:38 AM UTC